Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

228171

registered interest
date	18/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Inflammatory Bowel Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what funding there has been from the public purse for research into treatment of (a) Crohn's disease and (b) ulcerative colitis in the last five years.
tabling member constituency	Oxford East
tabling member printed	Mr Andrew Smith
uin	228177
answer	answer is ministerial correction date of answer 25/03/2015 answer text <p>The following table shows expenditure on research relating to the treatment of Crohn’s disease and ulcerative colitis by the Medical Research Council, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p>£ million</p><p> </p><table><tbody><tr><td><p> </p></td><td><p>2009/10</p></td><td><p>2010/11</p></td><td><p>2011/12</p></td><td><p>2012/13</p></td><td><p>2013/14</p></td></tr><tr><td colspan="6"><p>Crohn’s disease</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>3.1</p></td><td><p>3.4</p></td><td><p>2.6</p></td><td><p>2.4</p></td><td><p>2.5</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.4</p></td><td><p>0.6</p></td><td><p>0.3</p></td><td><p>0.8</p></td></tr><tr><td colspan="6"><p>Ulcerative colitis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>1.2</p></td><td><p>1.0</p></td><td><p>0.9</p></td><td><p>0.7</p></td><td><p>0.6</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.6</p></td><td><p>0.7</p></td><td><p>0.9</p></td><td><p>0.8</p></td><td><p>1.0</p></td></tr><tr><td colspan="6"><p>Crohn’s disease and ulcerative colitis</p></td></tr><tr><td><p>Medical Research Council<sup>1</sup></p></td><td><p>3.6</p></td><td><p>4.0</p></td><td><p>3.3</p></td><td><p>2.9</p></td><td><p>2.7</p></td></tr></tbody></table><p> </p><p><em>Note:</em></p><p> </p><p><sup>1</sup> Research looking at both Crohn’s disease and ulcerative colitis within the same project.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on research relating to the treatment of Crohn’s disease and ulcerative colitis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 25/03/2015 12:50:09 answering member 4020 label Biography information for George Freeman
tabling member	95 label Biography information for Mr Andrew Smith

225476

registered interest
date	05/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hepatitis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, which medicines his Department plans to include in the fast track interim policy for hepatitis C medicines.
tabling member constituency	Oxford East
tabling member printed	Mr Andrew Smith
uin	226494
answer	answer is ministerial correction date of answer 12/03/2015 answer text <p>NHS England has advised that it is considering extending the current interim commissioning policy for Sofosbuvir plus ledipasvir (Harvoni) and another direct acting antiviral combination therapy for selected patients with cirrhosis associated with hepatitis C. The Department is not involved in this decision.</p><p> </p><p> </p><p> </p><p>NHS England has completed the evidence review and finalised its draft proposals. In doing so, it has engaged with clinical and patient stakeholders from the national lead Clinical Reference Group. NHS England has advised that the aim is that interim commissioning policies will be in place by the first half of 2015.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 226492 226493 question first answered 12/03/2015 14:26:47 answering member 4020 label Biography information for George Freeman
tabling member	95 label Biography information for Mr Andrew Smith

225477

registered interest
date	05/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hepatitis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, who his Department and NHS England have consulted on the implementation of a fast track interim policy for hepatitis C patients from April 2015.
tabling member constituency	Oxford East
tabling member printed	Mr Andrew Smith
uin	226492
answer	answer is ministerial correction date of answer 12/03/2015 answer text <p>NHS England has advised that it is considering extending the current interim commissioning policy for Sofosbuvir plus ledipasvir (Harvoni) and another direct acting antiviral combination therapy for selected patients with cirrhosis associated with hepatitis C. The Department is not involved in this decision.</p><p> </p><p> </p><p> </p><p>NHS England has completed the evidence review and finalised its draft proposals. In doing so, it has engaged with clinical and patient stakeholders from the national lead Clinical Reference Group. NHS England has advised that the aim is that interim commissioning policies will be in place by the first half of 2015.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 226493 226494 question first answered 12/03/2015 14:26:46 answering member 4020 label Biography information for George Freeman
tabling member	95 label Biography information for Mr Andrew Smith

225478

registered interest
date	05/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hepatitis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what progress has been made on the delivery of a fast track interim policy for hepatitis C medicines for patients who need it from April 2015.
tabling member constituency	Oxford East
tabling member printed	Mr Andrew Smith
uin	226493
answer	answer is ministerial correction date of answer 12/03/2015 answer text <p>NHS England has advised that it is considering extending the current interim commissioning policy for Sofosbuvir plus ledipasvir (Harvoni) and another direct acting antiviral combination therapy for selected patients with cirrhosis associated with hepatitis C. The Department is not involved in this decision.</p><p> </p><p> </p><p> </p><p>NHS England has completed the evidence review and finalised its draft proposals. In doing so, it has engaged with clinical and patient stakeholders from the national lead Clinical Reference Group. NHS England has advised that the aim is that interim commissioning policies will be in place by the first half of 2015.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 226492 226494 question first answered 12/03/2015 14:26:47 answering member 4020 label Biography information for George Freeman
tabling member	95 label Biography information for Mr Andrew Smith